Omnicell, Inc. (NASDAQ:OMCL) Shares Purchased by Avory & Company LLC

Avory & Company LLC lifted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 25.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 193,162 shares of the company’s stock after purchasing an additional 39,386 shares during the period. Omnicell accounts for 5.1% of Avory & Company LLC’s holdings, making the stock its 9th biggest position. Avory & Company LLC owned about 0.42% of Omnicell worth $7,269,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently made changes to their positions in the stock. Pacer Advisors Inc. increased its holdings in shares of Omnicell by 321,488.8% during the 4th quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company’s stock worth $39,814,000 after acquiring an additional 1,057,698 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Omnicell by 15.1% during the 3rd quarter. Vanguard Group Inc. now owns 5,137,084 shares of the company’s stock worth $231,374,000 after buying an additional 674,824 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Omnicell by 12,425.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 482,488 shares of the company’s stock worth $21,731,000 after buying an additional 478,636 shares during the period. Assenagon Asset Management S.A. bought a new stake in shares of Omnicell during the 4th quarter worth about $13,687,000. Finally, Exchange Traded Concepts LLC grew its stake in Omnicell by 48.2% in the 4th quarter. Exchange Traded Concepts LLC now owns 566,704 shares of the company’s stock valued at $21,325,000 after buying an additional 184,213 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analysts Forecast Growth

OMCL has been the subject of a number of research analyst reports. Wells Fargo & Company reduced their price objective on Omnicell from $28.00 to $26.00 and set an “equal weight” rating for the company in a report on Friday, February 9th. Benchmark reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Omnicell in a report on Tuesday. Finally, Barclays began coverage on Omnicell in a report on Wednesday, January 3rd. They set an “underweight” rating and a $33.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $42.20.

Omnicell Price Performance

OMCL stock traded down $0.18 during midday trading on Tuesday, reaching $27.22. The company had a trading volume of 151,318 shares, compared to its average volume of 532,490. Omnicell, Inc. has a 1-year low of $25.69 and a 1-year high of $77.14. The stock has a 50 day moving average price of $27.64 and a 200-day moving average price of $32.04. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.52 and a quick ratio of 2.22. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -60.07 and a beta of 0.76.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 8th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.22. The company had revenue of $258.85 million during the quarter, compared to analysts’ expectations of $256.00 million. Omnicell had a negative net margin of 1.78% and a positive return on equity of 3.43%. Equities research analysts expect that Omnicell, Inc. will post 0.09 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.